Abstract
Objective
To investigate the effect of Longbishu Capsule (癃闭舒胶囊, LBS), doxazosin, and combination therapy on benign prostatic hyperplasia (BPH).
Methods
A randomized, double-blind, multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing (108 cases), Heilongjiang (90 cases), Sichuan (90 cases), Shanghai (72 cases), China. They were randomly assigned with central randomization method to group A (LBS placebo plus doxazosin), group B (LBS plus doxazosin) or group C (LBS plus doxazosin placebo), 120 cases for each group. The international prostate symptom score, maximum urinary flow rate, postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.
Results
At baseline, there was no significant difference in the measured variables among the three groups. After 12-month treatment, the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline (P<0.01). Although postvoid residual urine volume was not significantly different from the baseline in group A (P>0.05), it significantly decreased in group B and C (P<0.05). The incidence of adverse events were similar among the three groups.
Conclusions
The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH. The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kumar R, Malla P, Kumar M. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia. Expert Opin Drug Discov 2013;8:1013–1027.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–2398.
Cohen SA, Parsons JK. Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 2012;29:275–284.
Wang ZH. Effect of Longbishu Capsule on benign prostatic hyperplasia: an observational study. Nat J Androl 2005;11:873,879.
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–1557.
Zhang XH, Wang XH, Wang G, Wei Q, Xu CL, Xue W, et al. Diagnostic and treatment guidelines on benign prostatic hyperplasia of Chinese. Chin J Surgy (Chin) 2007;45:1704–1707.
Ministry of Health of People’s Republic of China. Guiding principle of clinical research of Chinese new drug (the first series). 1993:171.
Roehrborn CG, Girman CJ, Rhodes T, Hanson KA, Collins GN, Sech SM, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997;49:548–557.
Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient’s risk profile for progression. BJU Int 2005;95(Suppl 4):6–11.
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006:175:1422–1427.
Kolman C, Girman CJ, Jacobsen SJ, Lieber MM. Distribution of postvoid residual urine in randomly selected men. J Urol 1999;161:122–127.
Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:167–189.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–563.
Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996;155:595–600.
Wu SL, Yang CS, Duan JH, Xiao YX, Guo HF. Effecting of mechanism of Chinese drug Longbishu Capsule on patients with weaken destrusor. J Clin Urol 2010;25:464–465.
McNeill SA. Does acute urinary retention respond to alphablockers alone? Eur Urol 2001;39(Suppl 6):7–12.
O’Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003;62:15–23.
Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, et al. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study Int J Urol 2013;20:421–428.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Project of Science Research for the 11th Five Year Plan (No. 2007BAI20B044)
Rights and permissions
About this article
Cite this article
Song, Cs., Guo, J., Chang, Dg. et al. Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial. Chin. J. Integr. Med. 20, 818–822 (2014). https://doi.org/10.1007/s11655-014-1844-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-014-1844-0